Cat. No：GM-C26533
Product：H_CALCR RAMP3(AMY3) Reporter CHO-K1 Cell Line
Cat. No：GM-C26533
Product：H_CALCR RAMP3(AMY3) Reporter CHO-K1 Cell Line
Cell Growth Medium：F12K+10% FBS+1% P.S+4 μg/mL Blasticidin+200 μg/mL G418+4 μg/mL Puromycin
Cell Freezing Medium：90% FBS+10% DMSO
Assay Buffer：F12K +1% FBS+1% P.S
The calcitonin gene-related peptide (CGRP) family includes calcitonin, amylin, CGRP, and adrenomedullin.
Amylin has three potential receptors, all of which are complexes formed by calcitonin receptors (CALCR, CTR) and receptor activity-modifying proteins (RAMPs). The RAMPs are a series of type I transmembrane proteins that form heterodimers with G protein-coupled receptors, divided into three subtypes: RAMP1, RAMP2, and RAMP3. They have a large extracellular N-terminal domain, a single transmembrane domain, and a short cytoplasmic domain of around 10 amino acids. These three RAMPs have similar basic structures but only about 30% amino acid sequence identity. The complexes formed by CALCR and RAMP1, CALCR and RAMP2, and CALCR and RAMP3 are called AMY1, AMY2, and AMY3, respectively.
Amylin is produced by the pancreas and acts as a hormone to regulate nutrient intake. Research on amylin deposition in neurons primarily focuses on its role in Alzheimer's disease.
Upon binding of amylin to the receptor complex, the complex interacts with G proteins, leading to the separation of the Gαs subunit from the complex and activation of adenylate cyclase, resulting in cAMP production. The increase in intracellular cAMP levels stimulates the cAMP-dependent signaling pathway, ultimately leading to the induction of gene expression when cAMP response element-binding protein binds to the promoter.
The JM H_CALCR RAMP3 (AMY3) Reporter CHO-K1 Cell Line is a luciferase reporter cell line based on the cAMP signaling pathway. Upon amylin binding to CALCR/RAMPs, the activation of the cAMP signaling pathway leads to the expression of luciferase. The luciferase readout represents the activation effect of the signaling pathway and can be used to evaluate the in vitro effects of amylin-related drugs.
Cat. No：GM-C26533
Product：H_CALCR RAMP3(AMY3) Reporter CHO-K1 Cell Line
Cell Growth Medium：F12K+10% FBS+1% P.S+4 μg/mL Blasticidin+200 μg/mL G418+4 μg/mL Puromycin
Cell Freezing Medium：90% FBS+10% DMSO
Assay Buffer：F12K +1% FBS+1% P.S
The calcitonin gene-related peptide (CGRP) family includes calcitonin, amylin, CGRP, and adrenomedullin.
Amylin has three potential receptors, all of which are complexes formed by calcitonin receptors (CALCR, CTR) and receptor activity-modifying proteins (RAMPs). The RAMPs are a series of type I transmembrane proteins that form heterodimers with G protein-coupled receptors, divided into three subtypes: RAMP1, RAMP2, and RAMP3. They have a large extracellular N-terminal domain, a single transmembrane domain, and a short cytoplasmic domain of around 10 amino acids. These three RAMPs have similar basic structures but only about 30% amino acid sequence identity. The complexes formed by CALCR and RAMP1, CALCR and RAMP2, and CALCR and RAMP3 are called AMY1, AMY2, and AMY3, respectively.
Amylin is produced by the pancreas and acts as a hormone to regulate nutrient intake. Research on amylin deposition in neurons primarily focuses on its role in Alzheimer's disease.
Upon binding of amylin to the receptor complex, the complex interacts with G proteins, leading to the separation of the Gαs subunit from the complex and activation of adenylate cyclase, resulting in cAMP production. The increase in intracellular cAMP levels stimulates the cAMP-dependent signaling pathway, ultimately leading to the induction of gene expression when cAMP response element-binding protein binds to the promoter.
The JM H_CALCR RAMP3 (AMY3) Reporter CHO-K1 Cell Line is a luciferase reporter cell line based on the cAMP signaling pathway. Upon amylin binding to CALCR/RAMPs, the activation of the cAMP signaling pathway leads to the expression of luciferase. The luciferase readout represents the activation effect of the signaling pathway and can be used to evaluate the in vitro effects of amylin-related drugs.
